Goldman Sachs
ZEAL

Goldman Sachs’s Zealand Pharma A/S American Depositary Shares ZEAL Stock Holding History

Goldman Sachs’s Portfolio ZEAL Stock Details ZEAL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-500,916
Closed -$6.52M – 6783
2022
Q2 		$6.52M Buy
+500,916
New +$6.43M ﹤0.01% 2894
2017
Q4 		– Sell
-10,022
Closed -$192K – 6757
2017
Q3 		$192K Buy
+10,022
New +$189K ﹤0.01% 5778

Other funds holding ZEAL

TF
TimeScale Financial Danvers, Massachusetts $463M AUM 12.48% 1-Year Est. Return

Goldman Sachs's ZEAL Position: Q3 2022 in Review

Goldman Sachs sold out of Zealand Pharma A/S American Depositary Shares (ZEAL) in Q3 2022, closing a stake of 500,916 shares — an estimated $6.52M sold.

Goldman Sachs first reported a position in ZEAL in Q3 2017 and held it in 2 quarters. The position peaked at $6.52M in Q2 2022. 1 fund tracked by Wall St. Rank holds ZEAL as of Q3 2022.

  • Goldman Sachs reported no remaining Zealand Pharma A/S American Depositary Shares position as of Q3 2022 after selling out during the quarter.
  • Goldman Sachs sold 500,916 Zealand Pharma A/S American Depositary Shares shares in Q3 2022, an estimated $6.52M.
  • Goldman Sachs first reported a position in Zealand Pharma A/S American Depositary Shares in Q3 2017 and held it in 2 quarters.
  • Goldman Sachs's Zealand Pharma A/S American Depositary Shares position peaked at $6.52M in Q2 2022.
  • 1 fund tracked by Wall St. Rank held Zealand Pharma A/S American Depositary Shares as of Q3 2022.

Based on Goldman Sachs's 13F filing for Q3 2022, filed 14 Nov 2022.